Ceftobiprole Activity against Bacteria from Skin and Skin Structure Infections in the United States from 2016 through 2018
Robert K. Flamm, Leonard R Duncan, Kamal Hamed, Jennifer I. Smart, Rodrigo E. Mendes, Michael A. Pfaller
Abstract
Ceftobiprole medocaril is an advanced-generation cephalosporin prodrug that has qualified infectious disease product status granted by the US FDA and is currently being evaluated in phase 3 clinical trials in patients with acute bacterial skin and skin structure infections (ABSSSIs) and in patients with Staphylococcus aureus bacteremia. In this study, the activity of ceftobiprole and comparators was evaluated against more than 7,300 clinical isolates collected in the United States from 2016 through 2018 from patients with skin and skin structure infections.
Topics & Concepts
Staphylococcus aureusSkin infectionMedicineBacteremiaCephalosporinClinical trialInfectious disease (medical specialty)Staphylococcal Skin InfectionsProdrugAntibioticsIntensive care medicineDermatologyMicrobiologyBacteriaInternal medicineDiseasePharmacologyBiologyGeneticsAntimicrobial Resistance in StaphylococcusStreptococcal Infections and TreatmentsBacterial Identification and Susceptibility Testing